- Home
- CNX vs CORT Comparison
CNX vs CORT Comparison
Compare CNX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- CORT
- Stock Information
- Founded
- CNX 1860
- CORT 1998
- Country
- CNX United States
- CORT United States
- Employees
- CNX N/A
- CORT N/A
- Industry
- CNX Oil & Gas Production
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CNX Energy
- CORT Health Care
- Exchange
- CNX Nasdaq
- CORT Nasdaq
- Market Cap
- CNX 4.6B
- CORT 7.5B
- IPO Year
- CNX 1999
- CORT N/A
- Fundamental
- Price
- CNX $32.02
- CORT $72.98
- Analyst Decision
- CNX Hold
- CORT Strong Buy
- Analyst Count
- CNX 13
- CORT 4
- Target Price
- CNX $31.83
- CORT $142.00
- AVG Volume (30 Days)
- CNX 2.0M
- CORT 1.6M
- Earning Date
- CNX 07-24-2025
- CORT 07-28-2025
- Dividend Yield
- CNX N/A
- CORT N/A
- EPS Growth
- CNX N/A
- CORT 8.36
- EPS
- CNX N/A
- CORT 1.14
- Revenue
- CNX $1,579,627,000.00
- CORT $685,446,000.00
- Revenue This Year
- CNX $25.79
- CORT $35.83
- Revenue Next Year
- CNX $24.57
- CORT $35.24
- P/E Ratio
- CNX N/A
- CORT $63.26
- Revenue Growth
- CNX 19.15
- CORT 30.93
- 52 Week Low
- CNX $23.85
- CORT $29.42
- 52 Week High
- CNX $41.93
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CNX 48.62
- CORT 49.68
- Support Level
- CNX $31.96
- CORT $68.52
- Resistance Level
- CNX $34.29
- CORT $75.95
- Average True Range (ATR)
- CNX 0.98
- CORT 2.66
- MACD
- CNX -0.19
- CORT -0.13
- Stochastic Oscillator
- CNX 35.09
- CORT 42.13
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.